Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07645222 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jun 30, 2026 to Jun 15, 2026v2 Show 1 more changeShow less
    • Start date changed from estimate of Jun 30, 2026 to Jun 15, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT07645222
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Lung Cancer
Enrollment 396 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov